157 related articles for article (PubMed ID: 6872348)
21. Abnormal complement-mediated immune clearance in MRL-lpr/+ heterozygote mice: dose-dependent effect of the Fas antigen mutation.
Meryhew NL; Tam PE; Seim JK; Messner RP
Clin Immunol Immunopathol; 1996 Mar; 78(3):236-44. PubMed ID: 8605699
[TBL] [Abstract][Full Text] [Related]
22. Nephritogenicity of the lprcg gene on the MRL background.
Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice.
Hecht M; Müller M; Lohmann-Matthes ML; Emmendörffer A
J Leukoc Biol; 1995 Feb; 57(2):242-9. PubMed ID: 7852838
[TBL] [Abstract][Full Text] [Related]
24. Hepatic reticuloendothelial system activation in autoimmune mice: differences between (NZB X NZW)F1 and MRL-lpr/lpr strains.
Magilavy DB; Hundley TR; Steinberg AD; Katona IM
Clin Immunol Immunopathol; 1987 Mar; 42(3):386-98. PubMed ID: 3030589
[TBL] [Abstract][Full Text] [Related]
25. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.
Mountz JD; Smith HR; Wilder RL; Reeves JP; Steinberg AD
J Immunol; 1987 Jan; 138(1):157-63. PubMed ID: 3537128
[TBL] [Abstract][Full Text] [Related]
26. Specificity of monoclonal anti-Z-DNA antibodies from unimmunized MRL/Mp-lpr/lpr mice.
Bergen HR; Losman MJ; O'Connor T; Zacharias W; Larson JE; Accavitti MA; Wells RD; Koopman WJ
J Immunol; 1987 Aug; 139(3):743-8. PubMed ID: 3496387
[TBL] [Abstract][Full Text] [Related]
27. Resistance of MRL/Mp-lpr/lpr mice to tolerance induction.
Amagai T; Cinader B
Eur J Immunol; 1981 Nov; 11(11):923-6. PubMed ID: 6173230
[TBL] [Abstract][Full Text] [Related]
28. Spontaneous production of interleukin 3 by T lymphocytes from autoimmune MRL/MP-lpr/lpr mice.
Palacios R
Eur J Immunol; 1984 Jul; 14(7):599-605. PubMed ID: 6430708
[TBL] [Abstract][Full Text] [Related]
29. Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
Takahashi T; Yagi T; Kakinuma S; Kurokawa A; Okada T; Takatsu K; Aizawa S; Katagiri T
J Immunol; 1997 Sep; 159(5):2532-41. PubMed ID: 9278347
[TBL] [Abstract][Full Text] [Related]
30. Antibody to poly(ADP-ribose) as a predictor of obstetric complications in autoimmune MRL/Mp-lpr/lpr mice: basis for its application to pregnant patients with systemic lupus erythematosus.
Isonishi S; Kanai Y
Immunol Lett; 1988 May; 18(1):61-6. PubMed ID: 3378831
[TBL] [Abstract][Full Text] [Related]
31. Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes.
Rubio CF; Kench J; Russell DM; Yawger R; Nemazee D
J Immunol; 1996 Jul; 157(1):65-71. PubMed ID: 8683157
[TBL] [Abstract][Full Text] [Related]
32. Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice.
Furukawa F; Kanauchi H; Wakita H; Tokura Y; Tachibana T; Horiguchi Y; Imamura S; Ozaki S; Takigawa M
J Invest Dermatol; 1996 Jul; 107(1):95-100. PubMed ID: 8752846
[TBL] [Abstract][Full Text] [Related]
33. An epistatic effect of the female specific loci on the development of autoimmune vasculitis and antinuclear autoantibody in murine lupus.
Zhang MC; Misu N; Furukawa H; Watanabe Y; Terada M; Komori H; Miyazaki T; Nose M; Ono M
Ann Rheum Dis; 2006 Apr; 65(4):495-500. PubMed ID: 16150787
[TBL] [Abstract][Full Text] [Related]
34. Ocular inflammation in autoimmune MRL/Mp mice.
Jabs DA; Alexander EL; Green WR
Invest Ophthalmol Vis Sci; 1985 Sep; 26(9):1223-9. PubMed ID: 4030250
[TBL] [Abstract][Full Text] [Related]
35. Ocular inflammation in MRL/Mp-lpr/lpr mice.
Jabs DA; Prendergast RA
Invest Ophthalmol Vis Sci; 1991 May; 32(6):1944-7. PubMed ID: 2032814
[TBL] [Abstract][Full Text] [Related]
36. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
Sekine H; Reilly CM; Molano ID; Garnier G; Circolo A; Ruiz P; Holers VM; Boackle SA; Gilkeson GS
J Immunol; 2001 May; 166(10):6444-51. PubMed ID: 11342671
[TBL] [Abstract][Full Text] [Related]
37. Isotype progression and clonality of anti-Sm autoantibodies in MRL/Mp-lpr/lpr mice.
Eisenberg RA; Craven SY; Cohen PL
J Immunol; 1987 Aug; 139(3):728-33. PubMed ID: 3474277
[TBL] [Abstract][Full Text] [Related]
38. A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid.
Qu WM; Miyazaki T; Terada M; Okada K; Mori S; Kanno H; Nose M
Clin Exp Immunol; 2002 Jul; 129(1):27-34. PubMed ID: 12100019
[TBL] [Abstract][Full Text] [Related]
39. Stochastic control of anti-Sm autoantibodies in MRL/Mp-lpr/lpr mice.
Eisenberg RA; Craven SY; Warren RW; Cohen PL
J Clin Invest; 1987 Sep; 80(3):691-7. PubMed ID: 3624484
[TBL] [Abstract][Full Text] [Related]
40. VH gene expression is restricted in anti-IgG antibodies from MRL autoimmune mice.
Arant SE; Griffin JA; Koopman WJ
J Exp Med; 1986 Oct; 164(4):1284-300. PubMed ID: 3093628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
